« Return to News | Awards & Advancement

INC Research promotes Tierney to executive vice president, Asia/Pacific

Friday, March 1, 2013 02:47 PM

Therapeutically focused CRO INC Research has promoted Garth Tierney to executive vice president, Asia/Pacific, responsible for driving the strategic development and overall growth of Asia/Pacific clinical research operations. Tierney, who was INC Research’s regional general manager for Australia and Southeast Asia, co-founded Trident Clinical Research, an Australia-based CRO acquired by INC Research in 2011 after 14 years of operation.

"INC Research is experiencing tremendous opportunity to help drug developers navigate the diverse and complex landscape of conducting trials across the Asia/Pacific region, especially as many countries are poised to significantly increase their investment in clinical research," said Tierney.

Previously, Tierney worked for eight years in the clinical research industry in various senior management and operational management roles across several companies, including a global CRO, an Australian pharmaceutical company and two global pharmaceutical companies.

Tierney succeeds Kelvin Logan, Ph.D., who will retire in April. Dr. Logan joined INC Research in 2002 as its first employee outside North America and played an instrumental role in growing the EMEA and Asia/Pacific regions to 2,200 staff and 43 offices.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.